Description
As an integral step in the oncology drug discovery process, cell line derived xenograft models provide key decision-making information to allow an agent to move forward, and clients to advance their preclinical development programs in a timely and cost-effective manner. Crown Bioscience has established multiple in vivo assay systems to evaluate novel anticancer compounds, with each assay specifically designed to understand a drug's mechanism of action, or an individual agent property.